CS
FBRX icon

Credit Suisse’s Forte Biosciences FBRX Stock Holding History

Credit Suisse’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Hold
0
– – – 4106
2022
Q2 		– Hold
0
– – – 4041
2021
Q1 		– Sell
-3,406
Closed -$3.1M – 4374
2020
Q4 		$3.1M Sell
3,406
-3,818
-53% -$3.59M ﹤0.01% 2487
2020
Q3 		$8.76M Buy
+7,224
New +$4.79M 0.01% 1454

Other funds holding FBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse's FBRX Position: Q3 2022 in Review

Credit Suisse held its Forte Biosciences (FBRX) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4106.

Credit Suisse first reported a position in FBRX in Q3 2020 and has held it in 2 quarters since. The position peaked at $8.76M in Q3 2020. 33 funds tracked by Wall St. Rank hold FBRX as of Q3 2022.

  • Credit Suisse held 0 shares of Forte Biosciences worth $0 as of Q3 2022.
  • Credit Suisse left its Forte Biosciences share count unchanged in Q3 2022.
  • Forte Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4106 holding.
  • Credit Suisse first reported a position in Forte Biosciences in Q3 2020 and has held it in 2 quarters since.
  • Credit Suisse's Forte Biosciences position peaked at $8.76M in Q3 2020.
  • 33 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.